5-BROMO-2,6-DI-(1H-PYRAZOL-L-YL)PYRIMIDIN-4-AMINE FOR USE IN THE TREATMENT OF CANCER

FIELD: biology; medicine.SUBSTANCE: group of inventions relates to biotechnology and medicine. A pharmaceutical combination and a method for non-small-cell lung cancer treatment based on 5-bromo-2,6-di- (1H-pyrazol-1-yl) pyrimidin-4-amine, as well as the use of 5-bromo-2,6-di- (1H-pyrazol-1-yl) pyrimidin-4-amine for cancer treatment. The pharmaceutical combination contains a therapeutically effective amount of 5-bromo-2,6-di (1H-pyrazol-1-yl) pyrimidin-4-amine of formula (I):, the pharmaceutical combination contains a therapeutically effective amount of 5-bromo-2,6-di (1H-pyrazol-1-yl) pyrimidin-4-amine of formula (I): or a pharmaceutically acceptable salt thereof and one or more immunotherapeutic agents selected from the group, consisting of anti-CTLA4 antibodies, anti-PD-1 antibodies and anti-PD-L1 antibodies.EFFECT: oral administration of the compound of the formula (I) significantly reduces the tumor mass, in addition, the compound of the formula (I) has shown a synergistic effect with immunotherapeutic agents in stimulating the immune system for cancer treatment.31 cl, 10 dwg, 4 tbl, 4 ex